Semaglutide
Overview
Research-use GLP-1 receptor analogue supplied for studies of incretin signaling, glucose-regulation pathways, and metabolic models.
- Concentration
- 10 mg
- Stock
- In stock
Product details
Semaglutide is a modified GLP-1 receptor analogue used in research models of incretin signaling and metabolic pathway biology. Pattern lists this material for controlled laboratory research.
Research Targets: GLP-1 receptor signaling, pancreatic beta-cell pathway models, central appetite-regulation circuits, gastric-motility signaling.
Key Feature: Modified GLP-1 analogue with albumin-binding design elements for experimental pathway studies.
Research Focus Areas: Incretin biology, glucose-regulation pathway models, satiety signaling, metabolic response studies.
Common Models: Pancreatic beta-cell assays, rodent metabolic profiling, receptor-signaling systems.
Mechanistic Interests: GLP-1 receptor activation, insulin and glucagon signaling markers, cAMP pathway dynamics, gastric-emptying pathway models.
Use Boundary: Research use only; not for human or veterinary use; no diagnostic, therapeutic, or consumption use is implied.
Research context
Peptide guide
Open full guide- Guide profile
- GLP-1 Receptor Agonist
- Composition
- Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, a synthetic analog of the endogenous incretin hormone GLP-1 with structural modifications (including fatty acid conjugation) that extend its half-life to approximately one week
- Discovery
- Developed by Novo Nordisk as an evolution of earlier GLP-1 analogs like liraglutide
- Research scope
- Extensive Phase 3 clinical trials (SUSTAIN, STEP, SELECT, and others) involving tens of thousands of participants have established semaglutide's efficacy
- Regulatory status
- FDA-approved for type 2 diabetes, chronic weight management, cardiovascular-risk reduction in the labeled population, and Wegovy-specific MASH treatment in adults with moderate-to-advanced fibrosis; other uses are off-label or investigational
Safety context
- Personal/family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- Known hypersensitivity to semaglutide or any component
Research-use notice: Semaglutide has strong clinical evidence for approved diabetes, weight-management, cardiovascular-risk, and Wegovy-specific MASH indications. Benefits and risks should be interpreted through official labeling and trial populations; compounded or research-market formulations lack the same regulatory oversight.
Full guide includes 10 reference entries.
One kit adds 10 vials to WooCommerce checkout.